Compare Capri Holdings Ltd (CPRI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Neurocrine Biosciences Inc — how do they compare? Capri Holdings Ltd trades at $15.62 (market cap $1.75B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 9.6× Capri Holdings Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CPRI | NBIX | |
|---|---|---|
Market Cap | $1.75B | $16.76B |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $185.50 |
52-Week Low | $14.98 | $123.10 |
Enterprise Value | $3.03B | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $15.295, up 2.1% today but near 52-week lows after recent analyst downgrades. The stock shows bearish technical signals with moving averages indicating selling pressure, while fundamentals reveal mixed performance - strong gross margins of 62.71% but recent net losses and declining revenue. Recent Q1 2027 earnings beat expectations despite revenue challenges, with the company revising full-year guidance downward due to Michael Kors inventory delays and softer luxury demand.
The investment case hinges on successful execution of the post-Versace turnaround strategy, with Wall Street maintaining a cautious stance (44% buy ratings) despite a $19.60 consensus target representing 28% upside. Key risks include ongoing revenue declines, luxury market volatility, and execution challenges in revitalizing the Michael Kors brand amid competitive pressures.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
